ORMP
OramedFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Bull case assumes positive clinical/regulatory outcomes and at least one commercial partnership that validates the oral-protein delivery platform and materially expands addressable market, justifying a significant multiple re-rate and >70% upside from the anchor. Reviewer note: recent aggregator snippets show consensus targets near $3.25–3.32 (sanity check vs.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Clinical trial failure or negative data
Momentum
13
Value
42
Sentiment
45
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.30 · Bull $6.00 · Bear $1.80
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-09 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $6.25
Why
Momentum13 · Δ7d -
Value42 · Δ7d +0.1
Sentiment45 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
13
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
42
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
45
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 13.1 / Value 41.9 / Sentiment 45.0
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$159.2M
Beta
1.33
Shares Out
39.8M
P/E (TTM)
2.9
P/S (TTM)
58.91
P/FCF (TTM) · Derived
-15.77
Rev YoY
-100.0%
EPS YoY
+335.8%
Gross Margin
+0.7%
Op Margin
-650.5%
Net Debt
-$141.93M
Current Ratio
22.25
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology